Theranos Retracts Submission of Zika Blood Test to FDA

  • Testing firm didn’t use patient-safety protocol, Journal says
  • Controversial lab startup appealing proposed FDA sanctions

The Zika Virus Explained in Two Minutes

Theranos Inc. withdrew its submission for emergency clearance of a diagnostic blood test for the Zika virus after regulators found problems with how the blood-testing startup gathered patient data.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.